IE831728L - Sugar derivatives in the treatment of virus infections - Google Patents

Sugar derivatives in the treatment of virus infections

Info

Publication number
IE831728L
IE831728L IE831728A IE172883A IE831728L IE 831728 L IE831728 L IE 831728L IE 831728 A IE831728 A IE 831728A IE 172883 A IE172883 A IE 172883A IE 831728 L IE831728 L IE 831728L
Authority
IE
Ireland
Prior art keywords
formula
radical
group
substituted
independently
Prior art date
Application number
IE831728A
Other versions
IE55793B1 (en
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of IE831728L publication Critical patent/IE831728L/en
Publication of IE55793B1 publication Critical patent/IE55793B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1. A pharmaceutical composition for enteral or parenteral application, which composition contains, as sole active ingredient, an effective amount, but less than 1 % by weight, of a compound of the formula I see diagramm : EP0102319,P31,F1 in which the sugar moiety is derived from (D)-galactose, (D)-mannose or (D)-glucose, which compound has at an asymmetrically substituted C(-R**3) atom the (D)-configuration, at an asymmetrically substituted C(-R**6) atom the (L)-configuration and at an asymmetrically substituted C(-R**8) atom the (D)-configuration, and in which compound each of X**1 and X**2 independently to the other represents a group of the formula -O- or -N(R**14)-, R**14 representing hydrogen or lower alkyl, each of R**1, R**2, R**12 and R**13 independently represents a radical of the formula Ia -(Z**1-Y**1-X**3)n -A**1 in which n represents 0 or 1, Z**1 represents carbonyl or thiocarbonyl, Y**1 represents unsubstituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, X**3 represents a group of the formula -O- or -N(R**14)-, wherein R**14 has the meaning given above, and A**1 represents a radical of the formula Ib see diagramm : EP0102319,P31,F2 in which R**15 represents an aliphatic or cycloaliphatic radical having at least 7 carbon atoms, or A**1 represents a group of the formula Ic see diagramm : EP0102319,P31,F3 in which R**16 represents hydrogen and R**17 represents 2-hydroxyethyl or 1,2-dihydroxyethyl, wherein at least one hydroxy group is esterified or etherified by a radical having at least 7 carbon atoms, or in which each or R**16 and R**17 independently of the other represents esterified or etherified hydroxymethyl, the esterifying or etherifying radicals having at least 7 carbon atoms, or each of R**1, R**2, R**12 and R**13 independently represents hydrogen, acyl other than a radical of the formula Ia in which n represents 1, or aliphatically substituted silyl, each of R**3, R**4, R**5, R**7 and R**8 independently represents hydrogen or lower alkyl, R**6 represents hydrogen or lower alkyl that is unsubstituted or substituted by a group of the formula Id -E-(Z**2-Y**2-X**4)m -A**2 in which m represents 0 or 1, E represents a group of the formula -O-, -S- or -N(R**14), R**14 having the meaning given above, Z**2 represents carbonyl or thiocarbonyl, Y**2 represents unsubstituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, X**4 represents a group of the formula -O- or -N(R**14)-, having the meaning given above, and A**2 represents a radical of the formula Ib or lc ; or by free or etherified hydroxy or mercapto, by esterified hydroxy or mercapto other than a group of the formula Id, by free amino or substituted amino other than a group of the formula Id, by free, esterified or amidated carboxy, by cycloalkyl, by carbocyclic aryl or by nitrogen-containing heteroaryl having 5 or 6 ring members in the heterocyclic ring, or R**5 and R**6 together represent unsubstituted 1,3- or 1,4-lower alkylene, each of R**9 and R**11 independently of the other represents a radical of the formula Ie -X**5-Y**3-X**6-A**3 in which X**5 represents a group of the formula -O-, -S- or -N(R**14)-, and X**6 represents a group of the formula -O- or -N(R**14)-, in each case R**14 having the meaning given above, Y**3 represents unsubstituted or substituted alkylene which may be interrupted by iminocarbonyl or oxycarbonyl, and A**3 represents a radical of the formula Id or lc, or free hydroxy or mercapto, etherified hydroxy or mercapto other than a radical of the formula Ie, or free amino or substituted amino other than a radical of the formula Ie, and represents hydrogen or free, esterified or amidated carboxy, with the proviso that radicals qualified by the term "lower" contain up to and including 7 carbon atoms and that the compounds of the formula I have at least one radical A**1, A**2 or A**3 and/or a pharmaceutically acceptable salt thereof, together with a pharmaceutical carrier. [EP0102319A1]
IE1728/83A 1982-07-23 1983-07-22 Use of sugar derivatives for the prophylaxis and treatment of virus infections IE55793B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH452882 1982-07-23

Publications (2)

Publication Number Publication Date
IE831728L true IE831728L (en) 1984-01-23
IE55793B1 IE55793B1 (en) 1991-01-16

Family

ID=4277773

Family Applications (1)

Application Number Title Priority Date Filing Date
IE1728/83A IE55793B1 (en) 1982-07-23 1983-07-22 Use of sugar derivatives for the prophylaxis and treatment of virus infections

Country Status (12)

Country Link
EP (1) EP0102319B1 (en)
JP (1) JPS5933297A (en)
AU (1) AU566879B2 (en)
BE (1) BE897359A (en)
DE (1) DE3326163A1 (en)
HK (1) HK79890A (en)
IE (1) IE55793B1 (en)
IL (1) IL69294A (en)
IT (1) IT1168778B (en)
NZ (1) NZ205000A (en)
SG (1) SG77989G (en)
ZA (1) ZA835360B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3465087D1 (en) * 1983-03-04 1987-09-03 Merck & Co Inc Immunostimulatory dipeptidyl d-glucose derivatives and methods of preparation
FR2564096B1 (en) * 1984-05-11 1988-02-19 Anvar LIPOPHILIC DERIVATIVES OF MURAMYLPEPTIDES HAVING MACROPHAGE ACTIVATION PROPERTIES, COMPOSITIONS CONTAINING THEM AND PROCESS FOR OBTAINING THE SAME
EP0174912A3 (en) * 1984-09-13 1986-06-04 Ciba-Geigy Ag Phosphorus compounds, process for their preparations and their use
US4873322A (en) * 1986-01-24 1989-10-10 Ciba-Geigy Corporation Saccharide derivatives and processes for their manufacture
DE4305553A1 (en) * 1992-12-18 1994-06-23 Rhone Poulenc Rorer Gmbh Topical pharmaceutical or cosmetic compsn - contg. N-acyl-alkanolamine and phosphatidyl-ethanolamine derivs., e.g. for protecting skin against light or treating insect stings
GB9419011D0 (en) * 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
EP1735323B1 (en) * 2004-03-22 2017-08-30 Kode Biotech Limited Synthetic membrane anchors
CA3212571A1 (en) 2021-03-19 2022-09-22 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75578C (en) * 1979-07-25 1988-07-11 Ciba Geigy Ag Analogous procedure for the preparation of pharmacologically acting lipophilic a phosphatidylmuramyl peptides.
FI803077A (en) * 1979-10-12 1981-04-13 Ciba Geigy Ag FOERFARANDE FOER FRAMSTAELLNING AV MYRAMYLPEPTIDER
US4406889A (en) * 1980-02-15 1983-09-27 Ciba-Geigy Corporation Derivatives of aldohexoses, intermediates, processes for their manufacture, preparations containing such compounds, and their use
FR2498206A1 (en) * 1981-01-19 1982-07-23 Usinor ASYMMETRICAL LEAD SHEETS AND THEIR PREPARATION METHOD
GR78246B (en) * 1981-01-23 1984-09-26 Ciba Geigy Ag
US4697845A (en) * 1985-08-02 1987-10-06 The Quaker Oats Company Long-running motor-driven baby swing

Also Published As

Publication number Publication date
IE55793B1 (en) 1991-01-16
NZ205000A (en) 1986-08-08
SG77989G (en) 1990-09-07
AU1721983A (en) 1984-01-26
IL69294A0 (en) 1983-11-30
DE3326163A1 (en) 1984-01-26
BE897359A (en) 1984-01-25
IT8348734A0 (en) 1983-07-22
IL69294A (en) 1987-03-31
EP0102319A1 (en) 1984-03-07
HK79890A (en) 1990-10-12
JPS5933297A (en) 1984-02-23
IT1168778B (en) 1987-05-20
ZA835360B (en) 1985-03-27
AU566879B2 (en) 1987-11-05
EP0102319B1 (en) 1987-08-19

Similar Documents

Publication Publication Date Title
HUT59163A (en) Process for producing peptide derivatives and pharmaceutical compositions containing them
IL89576A0 (en) Peptide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
IL133891A0 (en) 2-valproenoic acid amide derivatives, their preparation and pharmaceutical compositions containing them
ZA909901B (en) Peptide compounds,a process for preparation thereof and pharmaceutical composition comprising the same
ES8606336A1 (en) 2-(N-substituteguanidino)-4-hetero-arylthiazole antiulcer agents.
NZ326238A (en) Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
IE831728L (en) Sugar derivatives in the treatment of virus infections
FI91076B (en) Process for the preparation of antibiotic C63 amide derivative of 34-de (acetylglucosaminyl) -34-deoxyticoplanins
KR910016689A (en) Urea derivatives and salts thereof, pharmaceutical compositions containing the same and methods for preparing the same
RU1804462C (en) Method of cefem compounds or theirs salts synthesis
JPS5645449A (en) Novel peptide, its pharmaceutically acceptable salt and preparation of the same
EP0331756A4 (en) Agents for prophylaxis and treatment of thrombopenia
KR950014130A (en) Glucosamine derivatives, preparation method thereof and synthetic intermediates thereof
MY101827A (en) 2-[n-substitutedguanidino]-4-heteroarylthiazole antiulcer agents
JO1228B1 (en) Process for the preparation of penam derivatives

Legal Events

Date Code Title Description
MK9A Patent expired